Today: 9 June 2026
UAMY stock jumps nearly 10% in premarket as antimony prices firm and China supply data hits tape
26 January 2026
2 mins read

UAMY stock jumps nearly 10% in premarket as antimony prices firm and China supply data hits tape

New York, Jan 26, 2026, 05:21 (EST) — Premarket

  • Shares of United States Antimony jumped nearly 10% in premarket trading following Friday’s close.
  • Antimony price benchmarks edged up during the session, fueling renewed interest in critical-minerals stocks.
  • Investors are eyeing follow-through after the open, with the next earnings date set for early April.

Shares of United States Antimony Corporation jumped roughly 10% in Monday’s premarket, pushing the NYSE American-listed UAMY to about $11.93, according to data from Public.com. Pre-market volume hit close to 218,000 shares.

Antimony prices climbed in the latest daily assessments. On Jan. 26, SMM’s benchmark for 1# antimony ingot rose roughly $270 to an average of $20,685.73 per metric ton. Meanwhile, the U.S. in-warehouse antimony price indicator (99.65% Sb min) held steady at $18.25 a pound.

Overnight, traders digested fresh supply data out of China. According to SMM, customs figures showed December 2025 imports of “other antimony ores and concentrates” climbed to 4,775.96 metric tons, up from 3,637.04 tons in November. Market watchers now anticipate a “significant” rebound in antimony prices from recent lows. Metal News

In another update, SMM reported that China’s antimony oxide exports jumped to 382.25 tons in December 2025, a 26.57% increase from November’s 302 tons, following several months of sluggish shipments. The group noted that a wider rebound in exports could boost confidence in antimony prices throughout 2026.

Company-specific action has slowed since last week, but investors remain focused on U.S. Antimony’s recent move to boost processing capacity. On Jan. 20, the company announced it finalized the purchase of a critical minerals flotation facility in Radersburg, Montana, for $4.75 million in cash. It also earmarked roughly $2 million for equipment upgrades. The facility is located less than 250 miles from its Thompson Falls smelter, where an expansion is reportedly “on track” for completion and commissioning by February. Nasdaq

A flotation mill employs chemicals and air bubbles to separate minerals from crushed ore—a crucial step miners take to concentrate feed before smelting. Chairman and CEO Gary C. Evans emphasized the company needs this facility “to properly concentrate the material” and produce “mil-spec” antimony trisulfide, which is reportedly used as a primer in ammunition. Nasdaq

U.S. Antimony’s latest SEC filing on its website is a Form 8-K dated Jan. 20. No updates appeared over the weekend.

Supply politics continue to weigh on investors beyond company news. China lifted its ban on exports of gallium, germanium, and antimony to the U.S. until Nov. 27, 2026, Reuters reported in November. However, these metals remain subject to wider export controls requiring licenses.

The metal market hasn’t followed a simple path. Fastmarkets reported that antimony prices surged to a record $59,750 per tonne in July 2025, then dropped as new smelters ramped up output and the steep costs curbed demand. This highlights how shifts in supply and substitution can quickly change the trade.

Investors will be watching closely after the bell to see if Monday’s early gains stick during regular hours and if antimony prices continue their strength following fresh China trade figures. U.S. Antimony is scheduled to report earnings next on April 6, per Investing.com.

Stock Market Today

  • Aperam (APEMY) Combines Fast Momentum and Value for Investors
    June 9, 2026, 10:49 AM EDT. Aperam (APEMY) is gaining attention as a solid choice for value investors seeking momentum stocks, with a 7.8% four-week price increase and a 55.8% gain over 12 weeks. The stock has a beta of 1.32, indicating it moves 32% more than the market, reflecting higher volatility and potential upside. Ranked #2 (Buy) with a strong Momentum Score of A, Aperam benefits from upward earnings estimate revisions from analysts. Its valuation remains attractive, trading at just 0.63 times its sales, suggesting investors pay only 63 cents per dollar of revenue. Aperam's combination of fast momentum and reasonable valuation makes it a compelling investment option amid market uncertainties.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Lloyds Banking Group share price lifts as profit-target talk grows ahead of results
Previous Story

Lloyds Banking Group share price lifts as profit-target talk grows ahead of results

The Impact of ChatGPT on Mental Health and Wellbeing: AI Therapy Boom Faces a Safety Reckoning
Next Story

The Impact of ChatGPT on Mental Health and Wellbeing: AI Therapy Boom Faces a Safety Reckoning

Go toTop